PFSA Stock Summary and Trading Ideas (Profusa | NASDAQ:PFSA)

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Profusa trades on the NASDAQ stock market under the symbol PFSA.

As of October 9, 2026, PFSA stock price declined to $1.42 with 216,720 million shares trading.

PFSA has a beta of 3.61, meaning it tends to be more sensitive to market movements. PFSA has a correlation of 0.06 to the broad based SPY ETF.

PFSA has a market cap of $860,131.00. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that PFSA belongs to (by Net Assets): VXF.

PFSA has underperformed the market in the last year with a price return of -99.9% while the SPY ETF gained +17.1%. PFSA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -86.0% and -34.9%, respectively, while the SPY returned +3.8% and +0.9%, respectively.

PFSA support price is $1.24 and resistance is $1.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFSA shares will trade within this expected range on the day.